FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | or Sect | ion 30(h) of | the Investment Company Act of 19 | 940 | | | |
|--|---|--------------------|--|---|------------------------------------|---|---|
| 1. Name and Address of Reporting Person* <u>Templeton Mary B Esq</u> | npleton Mary B Esq (First) (Middle) Requiring Statement (Month/Day/Year) 09/13/2011 | | 3. Issuer Name and Ticker or Trading Symbol DISCOVERY LABORATORIES INC /DE/ [DSCO] | | | | |
| (Last) (First) (Middle) 2600 KELLY RD | | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) | | er (Mo | 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) | |
| WARRINGTON PA 18976 | | | Senior VP, General | Counsel | | | by One Reporting Person by More than One Person |
| (City) (State) (Zip) | | | | | | | |
| | Table I - Nor | n-Derivat | tive Securities Beneficial | ly Owned | | | |
| 1. Title of Security (Instr. 4) | | | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownersh Form: Direct or Indirect (Instr. 5) | t (D) (Instr. 5) | | |
| Common Stock | | | 10,000(1) | D | | | |
| Common Stock | | | 7,826 ⁽²⁾ | I | By | Trust | |
| (| | | e Securities Beneficially ants, options, convertible | | s) | | |
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | d 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise | 5. Ownership Form: | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
| | Date Exercisable | Expiration Date | n Title | Amount or Number of Shares | Price of Derivative Security | Direct (D) or Indirect (I) (Instr. 5) | |
| Incentive Stock Option (right to buy) | 03/27/2006 | 03/27/2016 | Common Stock | 3,333 | 115.5 | D | |
| Incentive Stock Option (right to buy) | 05/17/2006 | 05/17/2016 | Common Stock | 444 | 33.75 | D | |
| Non-Qualified Stock Option (right to buy) | 05/17/2006 | 05/17/2016 | Common Stock | 2,889 | 33.75 | D | |
| Non-Qualified Stock Option (right to buy) | 12/15/2006 | 12/15/2016 | Common Stock | 4,667 | 36.9 | D | |
| Incentive Stock Option (right to buy) | 06/21/2007 | 06/21/2017 | Common Stock | 1,000 | 49.05 | D | |
| Non-Qualified Stock Option (right to buy) | 06/21/2007 | 06/21/2017 | Common Stock | 3,000 | 49.05 | D | |
| Incentive Stock Option (right to buy) | 12/11/2007 | 12/11/2017 | Common Stock | 1,167 | 39.15 | D | |
| Non-Qualified Stock Option (right to buy) | 12/11/2007 | 12/11/2017 | Common Stock | 3,500 | 39.15 | D | |
| Incentive Stock Option (right to buy) | 12/12/2008 | 12/12/2018 | Common Stock | 741 | 18.15 | D | |
| Non-Qualified Stock Option (right to buy) | 12/12/2008 | 12/12/2018 | 3 Common Stock | 1,481 | 18.15 | D | |
| Incentive Stock Option (right to buy) | 12/12/2008 | 12/12/2018 | Common Stock | 1,772 | 28.95 | D | |
| Non-Qualified Stock Option (right to buy) | 12/12/2008 | 12/12/2018 | Common Stock | 2,672 | 28.95 | D | |

Explanation of Responses:

1. Includes 6,667 Restricted Stock Awards, issued September 27,2010, that fully vest upon the earlier of (i) the second anniversary of the date of grant (ii) approval of Discovery Labs' New Drug Application for Surfaxin (R) for the prevention of RDS or (iii) the effective date of a strategic alliance, collaboration agreement or other similar arrangement between Discovery Labs and one of more third parties providing for the support for the development and/or commercialization of one or more of Discovery Lab's lead research and development programs - Surfaxin (R), Surfaxin LS (TM), and Aerosurf (R).

09/22/2011 Mary B> Templeton, Esq

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} Shares reported represent issuer's matching stock contributions pursuant to its 401(k) program.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).